Prime Medicine Inc (NASDAQ: PRME)’s stock price has gone decline by -13.33 in comparison to its previous close of 2.40, however, the company has experienced a -6.94% decrease in its stock price over the last five trading days. globenewswire.com reported 2025-02-28 that — On track to report initial data from Phase 1/2 clinical trial of PM359 for p47 phox CGD in 2025 — — IND-enabling studies ongoing for PM577 for Wilson’s Disease; expect to file IND and/or CTA in 1H 2026 — — Additional high-value programs advancing through preclinical development — CAMBRIDGE, Mass., Feb. 28, 2025 (GLOBE NEWSWIRE) — Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today reported financial results for the full year ended December 31, 2024 and provided a business update.
Is It Worth Investing in Prime Medicine Inc (NASDAQ: PRME) Right Now?
Company’s 36-month beta value is 1.75.Analysts have differing opinions on the stock, with 7 analysts rating it as a “buy,” 4 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for PRME is 51.92M, and currently, short sellers hold a 34.78% ratio of that floaft. The average trading volume of PRME on March 11, 2025 was 1.10M shares.
PRME’s Market Performance
PRME stock saw a decrease of -6.94% in the past week, with a monthly decline of -17.46% and a quarterly a decrease of -34.80%. The volatility ratio for the week is 10.32%, and the volatility levels for the last 30 days are 10.36% for Prime Medicine Inc (PRME). The simple moving average for the last 20 days is -19.40% for PRME’s stock, with a simple moving average of -49.52% for the last 200 days.
Analysts’ Opinion of PRME
Many brokerage firms have already submitted their reports for PRME stocks, with JMP Securities repeating the rating for PRME by listing it as a “Mkt Outperform.” The predicted price for PRME in the upcoming period, according to JMP Securities is $10 based on the research report published on December 10, 2024 of the previous year 2024.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see PRME reach a price target of $10. The rating they have provided for PRME stocks is “Buy” according to the report published on May 20th, 2024.
Citigroup gave a rating of “Buy” to PRME, setting the target price at $10 in the report published on May 16th of the previous year.
PRME Trading at -24.98% from the 50-Day Moving Average
After a stumble in the market that brought PRME to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -75.76% of loss for the given period.
Volatility was left at 10.36%, however, over the last 30 days, the volatility rate increased by 10.32%, as shares sank -15.79% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -25.98% lower at present.
During the last 5 trading sessions, PRME fell by -6.73%, which changed the moving average for the period of 200-days by -72.38% in comparison to the 20-day moving average, which settled at $2.58. In addition, Prime Medicine Inc saw -28.77% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for PRME
Current profitability levels for the company are sitting at:
- -4.97 for the present operating margin
- 0.99 for the gross margin
The net margin for Prime Medicine Inc stands at -4.81. The total capital return value is set at -0.78. Equity return is now at value -136.88, with -48.54 for asset returns.
Based on Prime Medicine Inc (PRME), the company’s capital structure generated 0.21 points at debt to capital in total, while cash flow to debt ratio is standing at -3.01.
Currently, EBITDA for the company is -202.47 million with net debt to EBITDA at 0.72. When we switch over and look at the enterprise to sales, we see a ratio of 3.22. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.58.
Conclusion
In a nutshell, Prime Medicine Inc (PRME) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
